FDA Approved: * July 5, 2002 Pharm Company: *MYLAN Category:Ulcer
Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.
It was patented in 1980 and approved for medical use in 1988. It was developed by Eli Lilly. Brand names include Tazac and Axid.
1 Medical use
2 Adverse effects
3 History and development
4 See also
6 External links
* May have multiple approval dates, manufacturers, or labelers. 3 Discussions